In this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer, 14 studies were included with a total of 3,328 patients. As the number of targetable mutations continues to increase and cancer care becomes even more complex, consultation with an interdisciplinary MTB can help guide therapy […]
In a study in the journal Nature Cancer, the researchers found that in laboratory cell lines and tumor models novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes, which help repair damaged DNA. The drug, developed in the 1950s and largely supplanted by newer drugs, was effective even in tumors resistant to agents […]
In this Original Investigation from JAMA Oncology, the authors seek to discover the characteristics that define modern randomized clinical trials (RCTs) in oncology and whether they differ from characteristics of RCTs from the preceding decades, as concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS) and marginal effect […]
How can oncologists successfully implement precision medicine strategies in diffuse large B-cell lymphoma (DLBCL)? In this review, the authors describe the recently proposed genomic categories of DLBCL and their potential use for personalized treatment, as well as the significant challenges they will present.